|Brand name(s), other common name(s)||Zydelig®|
|Drug type||Phosphoinositide 3-kinase (PI3K) delta inhibitor|
|How the drug is given||By mouth|
Indications and Usage
Idelalisib is FDA approved to treat patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. It is also approved to treat patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) or relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.
Side effects needing medical attention
Diarrhea, fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills, rash, neutropenia, hypertriglyceridemia, hyperglycemia, ALT elevations, and AST elevations.
Idelalisib is being approved with a Boxed Warning alerting patients and healthcare professionals of the following fatal and serious adverse reactions: hepatotoxicity (liver damage caused by a drug), severe diarrhea or colitis, pneumonitis, and intestinal perforation.